Saturday, March 2, 2024



Bayer’s Lung Cancer Treatment Earns FDA Breakthrough Therapy Designation

Bayer's innovative small molecule tyrosine kinase inhibitor (TKI) BAY 2927088 has received Breakthrough Therapy designation from the FDA for the treatment of unresectable or...

Bayer and Recursion Collaborate on Precision Oncology Research to Accelerate New Cancer Therapies

Bayer, the global pharmaceutical leader, and Recursion Pharmaceuticals, a US-based clinical-stage TechBio company, have announced a significant shift in their research collaboration towards precision...

Bayer Expands OCEANIC Clinical Program with New Study for Atrial Fibrillation Patients

In a significant development, Bayer has announced the expansion of its Phase III OCEANIC clinical development program with the initiation of OCEANIC-AFINA, a new...

Latest news

Sticky Image